Impact of (18)F-FDG PET/CT imaging in therapeutic decisions for malignant solitary fibrous tumor of the pelvis.
Impact of (18)F-FDG PET/CT imaging in therapeutic decisions for malignant solitary fibrous tumor of the pelvis.
复制标题
(18)F-FDG PET/CT 成像对盆腔恶性孤立性纤维瘤治疗决策的影响。
DOI：
10.1097/rlu.0b013e31828165c1
复制
发表时间：
2013
影响因子：
10.6
通讯作者：
Eary,JanetF
中科院分区：
文献类型：
--
作者：
Yan,Jinchun;Jones,RobinL;Lewis,DavidH;Eary,JanetF
局部高危软组织肉瘤患者是否给予新辅助化疗的决定通常是基于活检评估的肿瘤分级，但活检可能存在抽样偏倚的固有问题。结合SUV max和18f - fdg PET/CT评估的异质性可能是为个体患者量身定制治疗的其他关键组成部分，为指导选择最适合个体的治疗方案提供了有价值的参数。我们报告了1例代表性病例，描述了FDG PET/CT如何协助骨盆恶性孤立性纤维性肿瘤治疗的临床管理决策。
The decision to give neoadjuvant chemotherapy in patients with localized high-risk soft tissue sarcoma is often based on tumor grade evaluated from biopsies, but biopsies can have the inherent issue of sampling bias. Incorporation of SUV max and heterogeneity assessed by 18 F-FDG PET/CT could be other crucial components in the effort to tailor treatment to an individual patient, providing valuable parameters to guide the selection of the most appropriate management schedule for an individual. We present 1 representative case describing how FDG PET/CT can assist in clinical management decisions for treatment of malignant solitary fibrous tumor of the pelvis.